The effectiveness and costeffectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: A systematic review and decision model

Health Technology Assessment

Volumn 14, Issue 9, 2010, Pages 1-178

  Hemingway, H ^a   Henriksson, M ^b,c   Chen, R ^a   Damant, J ^a   Fitzpatrick, N ^a   Abrams, K ^d   Hingorani, A ^a   Janzon, M ^b   Shipley, M ^a   Feder, G ^e   Keogh, B ^f   Stenestrand, U ^b   McAllister, K ^a   Kaski, J C ^g   Timmis, A ^h   Palmer, S ^c   Sculpher, M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f Department of Health ^*  (United Kingdom)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN; HOMOCYSTEINE; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

AGE; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES MELLITUS; EMBASE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MATHEMATICAL MODEL; MEDLINE; META ANALYSIS; OBESITY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX; SEX DIFFERENCE; SMOKING; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; HEALTH CARE ORGANIZATION; HOSPITAL ADMISSION; NATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PROGNOSIS; REVIEW; RISK FACTOR; UNITED KINGDOM;

AGE FACTORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HEALTH CARE RATIONING; HUMANS; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RISK FACTORS; STATE MEDICINE; WAITING LISTS;

EID: 76249102243     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14090     Document Type: Article

References (230)

1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
2. Morrow DA, editor. Cardiovascular biomarkers: pathophysiology and disease management. 1st edn. Totowa, NJ: Humana Press; 2006.
3. Grunkemeier GL, Jin R. Receiver operating characteristic curve analysis of clinical risk models. Ann Thorac Surg 2001;72:323-6.
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
5. Aylin P, Alves B, Best N, Cook A, Elliott P, Evans SJ, et al. Comparison of UK paediatric cardiac surgical performance by analysis of routinely collected data 1984-96: was Bristol an outlier? Lancet 2001;358:181-7.
6. Darzi A. High quality care for all: NHS next stage review final report. London: Department of Health; 2008.
7. Department of Health. Trust, assurance and safety: The regulation of health professionals in the 21st century. London: The Stationery Office; 2007.
8. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass9grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.
9. NCEPOD. Death following a first time, isolated coronary artery bypass graft. The heart of the matter. A report of the National Confidential Enquiry into Patient Outcome and Death. London: NCEPOD; 2008.
10. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9-13.
11. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2008. Eur J Cardiovasc Prev Rehabil 2009;16(Suppl. 1):S43-47.
12. Aitsi-Selmi A, Shipley M, Hemingway H. Stable angina pectoris: comparison of trends in symptoms and diagnosed cases of angina from 1991 to 2003 with trends in MI mortality. EuroPrevent, Paris, 2008.
13. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation 2008;117:1526-36.
14. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003;89:848-53.
15. Javitz HS, Ward MM, Watson JB, Jaana M. Cost of illness of chronic angina. Am J Manag Care 2004;10(Suppl. 11):S358-69.
16. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 2006;295:1404-11.
17. Clayton TC, Lubsen J, Pocock SJ, Voko Z, Kirwan BA, Fox KA, et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ 2005;331:869.
18. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
19. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
20. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration*. Lancet 1994;344:563-70.
21. The Society of Cardiothoracic Surgeons of Great Britain and Ireland. Fifth National Adult Cardiac Surgical Database Report 2003. Improving outcomes for patients. Oxfordshire, UK: Dendrite Clinical Systems Ltd; 2004.
22. Black N, Langham S, Coshall C, Parker J. Impact of the 1991 NHS reforms on the availability and use of coronary revascularisation in the UK (1987-1995). Heart 1996;76(Suppl. 4):1-31.
23. Willcox S, Seddon M, Dunn S, Edwards RT, Pearse J, Tu JV. Measuring and reducing waiting times: a cross-national comparison of strategies. Health Aff (Millwood) 2007;26:1078-87.
24. Bernstein SJ, Rigter H, Brorsson B, Hilborne LH, Leape LL, Meijler AP, et al. Waiting for coronary revascularization: a comparison between New York State, The Netherlands and Sweden. Health Policy 1997;42:15-27.
25. Carroll RJ, Horn SD, Soderfeldt B, James BC, Malmberg L. International comparison of waiting times for selected cardiovascular procedures. JACC 1995;25:557-63.
26. Graham MM, Norris CM, Galbraith PD, Knudtson ML, Ghali WA. Quality of life after coronary revascularization in the elderly. Eur Heart J 2006;27:1690-8.
27. Legare JF, MacLean A, Buth KJ, Sullivan JA. Assessing the risk of waiting for coronary artery bypass graft surgery among patients with stenosis of the left main coronary artery. CMAJ 2005;173:371-5.
28. Sampalis J, Boukas S, Liberman M, Reid T, Dupuis G. Impact of waiting time on the quality of life of patients awaiting coronary artery bypass grafting. CMAJ 2001;165:429-33.
29. Raghavan R, Benzaquen BS, Rudski L. Timing of bypass surgery in stable patients after acute myocardial infarction. Can J Cardiol 2007;23:976-82.
30. Hemingway H, Crook AM, Feder G, Dawson JR, Timmis A. Waiting for coronary angiography: is there a clinically ordered queue? Lancet 2000;355:985-6.
31. Naylor CD, Morgan CD, Levinton CM, Wheeler S, Hunter L, Klymciw K, et al. Waiting for coronary revascularization in Toronto: 2 years' experience with a regional referral office. ¡CMAJ 1993;149:955-62.
32. Naylor CD, Baigrie RS, Goldman BS, Basinski A. Assessment of priority for coronary revascularisation procedures. Revascularisation Panel and Consensus Methods Group. Lancet 1990;335:1070-3.
33. Hadorn DC, Holmes AC. The New Zealand priority criteria project. Part 2: Coronary artery bypass graft surgery. BMJ 1997;314:135-8.
34. Hemingway H, Fitzpatrick NK, Gnani S, Feder G, Walker N, Crook AM, et al. Prospective validity of measuring angina severity with Canadian Cardiovascular Society class: The ACRE study. Can J Cardiol 2004;20:305-9.
35. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
36. NICE. Guide to the methods of technology appraisal. 2008.
37. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
38. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
39. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
40. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
41. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37.
42. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114:201-8.
43. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and Creactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
44. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6.
45. Inaguma D, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Inaba S, et al. Relationship between renal function at the time of percutaneous coronary intervention and prognosis in ischemic heart disease patients. Clin Exp Nephrol 2007;11:56-60.
46. Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, et al. Metabolic syndrome, Creactive protein, and prognosis in patients with established coronary artery disease. Am Heart J 2006;152:298-304.
47. Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, et al. Usefulness of combined high-sensitive Creactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coron Artery Dis 2008;19:187-93.
48. Fathi RB, Gurm HS, Chew DP, Gupta R, Bhatt DL, Ellis SG. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. Am Heart J 2005;150:1190-7.
49. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline Creactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
50. Crea F, Monaco C, Lanza GA, Maggi E, Ginnetti F, Cianflone D, et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol 2002;25:461-6.
51. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of Creactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006;114:281-8.
52. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. Creactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
53. J, Collins R, Appleby P, Peto R. Association of fibrinogen, Creactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
54. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:217-31.
55. Di AE, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007;4:e270.
56. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
57. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
58. Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group; 2001.
59. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of Creactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006;27:2962-8.
60. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
61. Falcone C, Minoretti P, D'Angelo A, Buzzi MP, Coen E, Emanuele E, et al. Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease. Eur J Clin Invest 2006;36:211-17.
62. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006;27:150-6.
63. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004;44:1819-24.
64. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of Creactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
65. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Yui Y, et al. Fibrinolytic factors, serum lipid and Creactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions. Jpn Circ J 1999;63:976-80.
66. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy, lipid levels, Creactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-80.
67. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
68. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
69. Schaan BD, Quadros AS, Sarmento-Leite R, De LG J, Bender A, et al. Correction: Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with preexistent coronary artery disease. Cardiovasc Diabetol 2007;6:19.
70. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001;103:45-51.
71. Ndrepepa G, Kastrati A, Braun S, Koch W, Kolling K, Mehilli J, et al. A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clin Chim Acta 2006;373:70-6.
72. Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis 2002;164:371-8.
73. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (Creactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-8.
74. Saleh N, Braunschweig F, Jensen J, Tornvall P. Usefulness of preprocedural serum N-terminal probrain natriuretic peptide levels to predict long-term outcome after percutaneous coronary intervention in patients with normal troponin T levels. Am J Cardiol 2006;97:830-4.
75. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoproteinassociated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at followup. Eur Heart J 2005;26:137-44.
76. Chirinos JA, Zambrano JP, Chakko S, Schob A, Goldberg RB, Perez G, et al. Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation 2005;112:2446-53.
77. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001;103:3062-8.
78. Chirinos JA, Zambrano JP, Chakko S, Schob A, Veerani A, Perez GO, et al. Usefulness of Creactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005;95:88-90.
79. Qi X, Li S, Li J. The prognostic value of IL-8 for cardiac events and restenosis in patients with coronary heart diseases after percutaneous coronary intervention. Jpn Heart J 2003;44:623-32.
80. Qi X, Li J, Gu J, Li S, Dang Y, Wang T. Plasma levels of IL-8 predict early complications in patients with coronary heart disease after percutaneous coronary intervention. Jpn Heart J 2003;44:451-61.
81. Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. Creactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 2000;21:1598-606.
82. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-42.
83. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-7.
84. Arroyo ER. Creactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;25:401-8
85. Susen S, Sautiere K, Mouquet F, Cuilleret F, Chmait A, McFadden EP, et al. Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. Eur Heart J 2005;26:2387-95.
86. Dai DF, Lin JW, Kao JH, Hsu CN, Chiang FT, et al. The effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. J Clin Endocrinol Metab 2007;92:2532-7.
87. Dai DF, Hwang JJ, Lin JL, Lin JW, Hsu CN, Lin CM, et al. Joint effects of N-terminal pro-Btypenatriuretic peptide and Creactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease. Circ J 2008;72:1316-23.
88. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, et al. Clinical utility of Creactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008;51:2339-46.
89. Haim M, Tanne D, Goldbourt U, Doolman R, Boyko V, Brunner D, et al. Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease. Cardiology 2007;107:52-6.
90. Artieda M, Cenarro A, Ganan A, Lukic A, Moreno E, Puzo J, et al. Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of Creactive protein. Cardiology 2007;108:297-306.
91. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 2008;29:923-31.
92. Palmerini T, Marzocchi A, Marrozzini C, Reggiani LB, Savini C, Marinelli G, et al. Preoperative Creactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis. Eur J Cardiothorac Surg 2007;31:685-90.
93. Niccoli G, Ferrante G, Mongiardo R, Perfetti M, Belloni F, Burzotta F, et al. Cardiovasc Revasc Med 2007;8:156-60.
94. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. Predictive value of coronary artery stenoses and Creactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009;204:239-43.
95. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophillymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008;395:27-31.
96. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008;124:319-25.
97. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008;121:50-7.
98. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Schnabel R, Munzel T, et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007;195:e126-34.
99. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569-74.
100. Marcinkowski M, Czarnecka D, Jastrzebski M, Fedak D, Kawecka-Jaszcz K. Inflammatory markers 10 weeks after myocardial infarction predict future cardiovascular events. Cardiol J 2007;14:50-8.
101. Fang Y, Huang L, Li A, Song Y, Geng Z, et al. Significance of the ratio of circulating endothelial cell expressing endothelial lipase and supersensitivity Creactive protein in prognosis of patients with coronary arterty disease. Chin Crit Care Med 2007; 19:644-6.
102. Khor LL, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Maycock CA, et al. Sex- and age-related differences in the prognostic value of Creactive protein in patients with angiographic coronary artery disease. Am J Med 2004;117:657-64.
103. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. Creactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632-7.
104. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung C. Do associations with Creactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003;42:57-63.
105. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of highsensitivity Creactive protein in predicting longterm risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002;89:145-9.
106. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-9.
107. Schnabel R, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Torzewski M, Lubos E, et al. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. J Am Coll Cardiol 2005;45:1631-7.
108. Kangasniemi OP, Biancari F, Luukkonen J, Vuorisalo S, Satta J, Pokela R, et al. Preoperative Creactive protein is predictive of long-term outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg 2006;29:983-5.
109. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, et al. Cytomegalovirus seropositivity and Creactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000;102:1917-23.
110. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824-32.
111. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between Creactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003;114:715-22.
112. Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemoller K, von Beckerath N, et al. N-terminal probrain natriuretic peptide and Creactive protein in stable coronary heart disease. Am J Med 2006;119:355-8.
113. Blankenberg S, Rupprecht HJ, Bickel C, Espinola- Klein C, Rippin G, Hafner G, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 2001;103:2915-21.
114. de Winter RJ, Heyde GS, Koch KT, Fischer J, van Straalen JP, Bax M, et al. The prognostic value of pre-procedural plasma Creactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002;23:960-6.
115. AJJ, Serruys PW, Scholte J, Kleimeneij F, Slagboom T, Van der Weiken LR, et al. Direct coronary stent implantation does not reduce the incidence of in-stent restenosis or major adverse cardiac events: Six month results of a randomized trial. Eur Heart J 2003;24:421-9.
116. de Winter RJ, Koch KT, van Straalen JP, Heyde G, Bax M, Schotborgh CE, et al. Creactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115:85-90.
117. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 2005;35:537-45.
118. Janoskuti L, Forhecz Z, Hosszufalusi N, Kleiber M, Walentin S, Balint O, et al. High levels of Creactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease. Eur J Clin Invest 2005;35:104-11.
119. Veselka J, Prochazkova S, Duchonova R, Homolova I, Tesar D. Relationship of Creactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention for stable angina pectoris. Int Heart J 2005;46:195-204.
120. Low AF, Seow SC, Yeoh KG, Lim YT, Tan HC, Yeo TC. High-sensitivity Creactive protein is predictive of medium-term cardiac outcome in high-risk Asian patients presenting with chest pain syndrome without myocardial infarction. Ann Acad Med Singapore 2004;33:407-12.
121. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity Creactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007;99:31-5.
122. Leu HB, Lin CP, Lin WT, Wu TC, Chen JW. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity Creactive protein. Chest 2004;126:1032-9.
123. de Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004;94:1481-5.
124. Ikonomidis I, Lekakis J, Revela I, Andreotti F, Nihoyannopoulos P. Increased circulating Creactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005;26:1618-24.
125. Karha J, Bavry AA, Rajagopal V, Henderson MR, Ellis SG, Brener SJ. Relation of Creactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol 2006;98:616-18.
126. Kinjo K, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, et al. Impact of high-sensitivity Creactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 2003;91:931-5.
127. Kwaijtaal M, van Diest R, Bar FW, van der Ven AJ, Bruggeman CA, de Baets MH, et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis 2005;182:341-8.
128. Zairis MN, Ambrose JA, Lyras AG, Thoma MA, Psarogianni PK, Psaltiras PG, et al. Creactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: four year results from the GENERATION study. Heart 2004;90:419-24.
129. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, et al. The impact of plasma levels of Creactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:1375-82.
130. Aytekin S, Catakoglu AB, Aytekin, Kocazeybek B, Demiroglu C, Demiroglu C. Creactive protein as a pre-procedural predictor of early and late outcomes of percutaneous coronary interventions. Int J Angiol 2003;12:229-33.
131. Sargento L, Do Rosario HS, Perdigao C, Monteiro J, Saldanha C, Silva JM. [Biohemorheologic factors and cardiovascular events curve in survivors of transmural acute myocardial infarct--24-month follow-up]. Rev Port Cardiol 2002;21:165-71.
132. Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Bacchi-Reggiani L, et al. Preprocedural levels of Creactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005;112:2332-8.
133. Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, et al. Relation of Creactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 2005;96:617-21.
134. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:191-9.
135. Biancari F, Lahtinen J, Lepojarvi S, Rainio P, Salmela E, Pokela R, et al. Preoperative Creactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg 2003;76:2007-12.
136. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, et al. Predictive value of Creactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-18.
137. van der HP, Voors AA, Volbeda M, Buikema H, van Veldhuisen DJ, van Gilst WH. Usefulness of preoperative Creactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol 2006;97:1697-701.
138. Huang W, Chen QW, Lei H, Deng W, Ke DZ. [Predictive value of fibrinogen and high-sensitivity C-reaction protein for cardiovascular events in patients with stable coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:718-21.
139. D, Biasucci LM, Luciani N, Martinelli L, Canosa C, Schiavello R, et al. Elevated levels of Creactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-61, A9.
140. Palazzuoli A, Dekkers J, Calabro A, Campagna MS, Nuti R, Pastorelli M, et al. Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-st-elevation coronary syndromes and preserved systolic function. Am J Cardiol 2006;15:1322-8.
141. Muhlestein JB, Anderson JL, Horne BD, Carlquist JF, Bair TL, Bunch TJ, et al. Early effects of statins in patients with coronary artery disease and high Creactive protein. Am J Cardiol 2004;94:1107-12.
142. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/ American Heart Association high-sensitivity Creactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-36.
143. Saleh N, Svane B, Hansson LO, Jensen J, Nilsson T, Danielsson O, et al. Response of serum Creactive protein to percutaneous coronary intervention has prognostic value. Clin Chem 2005;51:2124-30.
144. Rahel BM, Visseren FL, Suttorp MJ, Plokker TH, Kelder JC, de Jongh BM, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res 2003;60:136-40.
145. Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, et al. High-sensitivity Creactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002;144:449-55.
146. Kubica J, Kozinski M, Krzewina-Kowalska A, Zbikowska-Gotz M, Dymek G, Sukiennik A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 2005;16:173-80.
147. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, et al. Prognostic impact of preprocedural Creactive protein levels on six-month angiographic and one-year clinical outcomes after drug-eluting stent implantation. Heart 2007;93:1087-92.
148. Grander W, Dichtl W, Prokop W, Roithinger FX, Moes N, Friedrich G, et al. Creactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention. Clin Cardiol 2004;27:211-16.
149. Lee KW, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 2006;174:461-6.
150. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, Creactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006;166:2455-60.
151. Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, et al. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J 2005;150:900-6.
152. Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, et al. Association of Creactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002;89:216-21.
153. Hoffmeister Rothenbacker D, Kunze M, Brenner H, Koenig W. Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease. Eur J Intern Med 2005:16:47-62.
154. Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. Creactive protein predicts death in patients with previous premature myocardial infarction -a 10 year follow-up study. Atherosclerosis 2002;160:433-40.
155. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. Analysis of N-terminal-probrain natriuretic peptide and Creactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005;26:241-9.
156. Patti G, Di SG, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:372-6.
157. Krzewina-Kowalska A, Kubica J, Kozinski M, Piasecki R, Berent B, et al. Selected acute phase proteins in patients undergoing coronary angioplasty. Folia Cadiol 2003;10:733-42.
158. Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike AI, Gibson G, et al. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J 2007;154:995-1002.
159. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796-801.
160. Lipsic E, Asselbergs FW, Van-Der-Meer?. Anaemia predicts cardiovascular events in patients with stable coronary artery disease. Neth Heart J 2005;13:254-8.
161. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 2003;24:2142-50.
162. Hillis GS, Croal BL, Buchan KG, El Shafei H, Gibson G, Jeffrey RR, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006;113:1056-62.
163. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003;14:2373-80.
164. Tang WH, Steinhubl SR, Van Lente F, Brennan D, McErlean E, Maroo A, et al. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J 2007;153:36-41.
165. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003;138:81-9.
166. Zakeri R, Freemantle N, Barnett V, Lipkin GW, Bonser RS, Graham TR, et al. Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005;112(Suppl. 9):I270-5.
167. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001;38:705-11.
168. Almquist T, Forslund L, Rehnqvist N, Hjemdahl P. Prognostic implications of renal dysfunction in patients with stable angina pectoris. J Intern Med 2006;260:537-44.
169. Shlipak MG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK, et al. Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 2004;43:37-44.
170. Solomon SD, Rice MM, Jablonski A, Jose P, Domanski M, Sabatine M, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114:26-31.
171. Chen R, Kumar S, Timmis A, Feder G, Yaqoob MM, Hemingway H. Comparison of the relation between renal impairment, angiographic coronary artery disease, and long-term mortality in women versus men. Am J Cardiol 2006;97:630-2.
172. Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res 2007;100:1234-41.
173. Shah B, Kumar N, Garg P, Kang E, Grossi E, Lorin JD, et al. Metabolic syndrome does not impact survival in patients treated for coronary artery disease. Coron Artery Dis 2008;19:71-7.
174. Ruilope LM, Kirwan BA, de Brouwer S, Danchin N, Fox KA, Wagener G, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007;25:1711-18.
175. Exaire JE, Butman SM, Ebrahimi G, Kleimen NS, Harrington RA, Schweiger MJ. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006;152:157-63.
176. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 1993;36:497-503.
177. Hu R, Ma CS, Nie SP, Lu Q, Kang JP, Du X, et al. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease. Chin Med J (Engl) 2006;119:1871-6.
178. Stassano P, Di Tommaso L, Vitale DF, Monaco M, Iannelli G, Mottola M, et al. Aortic valve replacement and coronary artery surgery: determinants affecting early and long-term results. Thorac Cardiovasc Surg 2006;54:521-7.
179. DiMauro M, Gagliardi M, Iaco AL, Contini M, Bivona A, Bosco P, et al. Does off-pump coronary surgery reduce postoperative acute renal failure? The importance of preoperative renal function. Ann Thorac Surg 2007;84:1496-1502.
180. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004;110:271-7.
181. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 2006;97:993-6.
182. Elisheva S, Noya G, Simchen E, Galai N, Zitser-Gurevich Y, Braun D, et al. Sequential logistic models for 30 days mortality after CABG: Preoperative, intra-operative and post-operative experience -The Israeli CABG study (ISCAB). Eur J Epidemiol 2000;16:543-55.
183. Cesena FH, Favarato D, Cesar LA, de Oliveira SA, Da Luz PL. Cardiac complications during waiting for elective coronary artery bypass graft surgery: incidence, temporal distribution and predictive factors. Eur J Cardiothorac Surg 2004;25:196-202.
184. van Domburg RT, Takkenberg JJ, van Herwerden LA, Venema AC, Bogers AJ. Short-term and 5-year outcome after primary isolated coronary artery bypass graft surgery: results of risk stratification in a bilocation center. Eur J Cardiothorac Surg 2002;21:733-40.
185. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 2002;105:2253-8.
186. Yamamuro M, Lytle BW, Sapp SK, Cosgrove DM, III, Loop FD, McCarthy PM. Risk factors and outcomes after coronary reoperation in 739 elderly patients. Ann Thorac Surg 2000;69:464-74.
187. Weerasinghe A, Hornick P, Smith P, Taylor K, Ratnatunga C. Coronary artery bypass grafting in non-dialysis-dependent mild-to-moderate renal dysfunction. J Thorac Cardiovasc Surg 2001;121:1083-9.
188. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005;149:606-12.
189. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
190. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654-64.
191. HM Treasury. The Green Book. Appraisal and evaluation in central government. London, The Stationery Office; 2003.
192. Jackson NW, Doogue MP, Elliott JM. Priority points and cardiac events while waiting for coronary bypass surgery. Heart 1999;81:367-73.
193. Henriksson M, Epstein DM, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, et al. The costeffectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 2008;94:717-23.
194. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of non- ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol 2005;100:229-40.
195. Collett D. Modelling survival data in medical research. London, Chapman and Hall/CRC; 1994.
196. Greene W. Econometric analysis. New York, Prentice Hall; 2003.
197. Bray H. 2006-based national population projections for the UK and constituent countries. Population trends. Government Actuary Department; 2006. www.gad. gov.uk/. 198. National Statistics. Review of the registrat general on dealths by cause, sex and age, in England and Wales. London, National Statistics; 2003.
198. National Statistics. Review of the registrat general on dealths by cause, sex and age, in England and Wales. London, National Statistics; 2003.
199. Department of Health. NHS reference costs 2005-06. London: Department of Health; 2006.
200. M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess 2005;9(27):iii-xi, 1.
201. L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. Clinical effectiveness and costeffectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8(38):iii-196.
202. HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
203. Cosin-Sales J, Kaski JC, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005;26:2093-8.
204. Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med 2000;19:141-60.
205. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
206. McCullagh P, Nelder JA. Generalized linear models. 2nd edn. London, Chapman and Hall; 1989.
207. Drummond MF, Sculpher M.J., Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
208. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.
209. Thompson SG, Duckert F, Haverkate F, Thomson JM. The measurement of haemostatic factors in 16 European laboratories: quality assessment for the Multicentre ECAT Angina Pectoris Study. Report from the European Concerted Action on Thrombosis and Disabilities (ECAT). Thromb Haemost 1989;61:301-6.
210. Ye Z, Song H, Higgins JP, Pharoah P, Danesh J. Five glutathione S-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: metaanalysis of 130 studies. PLoS Med 2006;3:e91.
211. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-55.
212. Kyzas PA, axa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43:2559-79.
213. Daly CA, Clemens F, Lopez Sendon JL, Tavazzi L, BOERSMA E, Danchin N, et al. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:1011-22.
214. Hemingway H, Crook AM, Feder G, Banerjee S, Dawson JR, Magee P, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med 2001;344:645-54.
215. Feder G, Crook AM, Magee P, Banerjee S, Timmis AD, Hemingway H. Ethnic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography. BMJ 2002;324:511-16.
216. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97.
217. Daly CA, De SB, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ 2006;332:262-7.
218. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
219. Schnabel R, Blankenberg S. Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation 2007;116:1338-40.
220. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-8.
221. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: an empirical assessment. PLoS Med 2007;4:e79.
222. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
223. Hemingway H. Prognosis research: why is Dr Lydgate still waiting? J Clin Epidemiol 2006;59:1229-38.
224. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-8.
225. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline Creactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
226. de Winter RJ, Heyde GS, Koch KT, Fischer J, van Straalen JP, Bax M, Schotborgh CE, et al. The prognostic value of pre-procedural plasma Creactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002;23:960-6.
227. de Winter RJ, Koch KT, van Straalen JP, Heyde GH, Bax M, Schotborgh CE, et al. Creactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115:85-90.
228. de Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004;94:1481-5.
229. Veselka J, Prochazkova S, Duchonova R, Homolova I, Tesar D. Relationship of Creactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention for stable angina pectoris. Int Heart J 2005;46:195-204.
230. Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 2009; 339:b4184. doi: 10.1136/bmjb4184.